A Case of Adjuvant Brigatinib in a Patient with ALK-rearranged R0 Resected Oligometastatic Lung Cancer

ZAnaplastic lymphoma kinase (ALK) rearrangement is detected at a low rate in non-small cell lung cancer (NSCLC).Patients with ALK rearrangements have poor responses to conventional cytotoxic chemotherapy.Brigatinib is one of the ALK-tyrosine kinase inhibitors recommended for first-line treatment in metastatic NSCLC.Local ablative therapies are applied in the treatment of oligometastatic disease in NSCLC.In this case, a patient with lung adenocarcinoma with ALK-rearranged isolated adrenal metastasis was treated with adjuvant brigatinib after sequential surgery.A 23-month disease-free survival was obtained.The case reported here represents the use of adjuvant therapy with ALK inhibitors in ALK-positive oligometastatic NSCLC in eligible patients.